BR112017018703A2 - peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno - Google Patents

peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno

Info

Publication number
BR112017018703A2
BR112017018703A2 BR112017018703-5A BR112017018703A BR112017018703A2 BR 112017018703 A2 BR112017018703 A2 BR 112017018703A2 BR 112017018703 A BR112017018703 A BR 112017018703A BR 112017018703 A2 BR112017018703 A2 BR 112017018703A2
Authority
BR
Brazil
Prior art keywords
gpc3
treating
pharmaceutical composition
same
presenting cells
Prior art date
Application number
BR112017018703-5A
Other languages
English (en)
Japanese (ja)
Inventor
Miyakawa Tomoya
Oka Masaaki
Hazama Shoichi
Tamada Koji
Udaka Keiko
Original Assignee
Cytlimic Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytlimic Inc. filed Critical Cytlimic Inc.
Publication of BR112017018703A2 publication Critical patent/BR112017018703A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção fornece um peptídeo contendo 8 ou mais resíduos de aminoácido consecutivos em uma sequência de aminoácido representada por qualquer de seq id nos: 1 a 11 e compreendendo 11 ou menos resíduos de aminoácido.
BR112017018703-5A 2015-03-09 2016-03-09 peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno BR112017018703A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015046463 2015-03-09
JP2015-046463 2015-03-09
PCT/JP2016/057356 WO2016143816A1 (ja) 2015-03-09 2016-03-09 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法

Publications (1)

Publication Number Publication Date
BR112017018703A2 true BR112017018703A2 (pt) 2018-04-17

Family

ID=56880605

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018703-5A BR112017018703A2 (pt) 2015-03-09 2016-03-09 peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno

Country Status (12)

Country Link
US (3) US10526388B2 (pt)
EP (1) EP3269733B1 (pt)
JP (1) JP6898225B2 (pt)
CN (2) CN113388021A (pt)
AU (1) AU2016230125B2 (pt)
BR (1) BR112017018703A2 (pt)
CA (1) CA2979168A1 (pt)
DK (1) DK3269733T3 (pt)
ES (1) ES2805829T3 (pt)
RU (1) RU2714117C2 (pt)
TW (2) TW202115102A (pt)
WO (1) WO2016143816A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
EP3925968A3 (en) 2014-10-07 2022-03-02 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
AU2016230125B2 (en) 2015-03-09 2020-07-16 Nec Corporation Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
EP3797794A1 (en) 2015-04-07 2021-03-31 Cytlimic Inc. Medicine comprising a toll like receptor 3 agonist and a lag-3 protein
AU2017342189B2 (en) * 2016-10-11 2023-09-21 Nec Corporation Medicine
US20220204560A1 (en) * 2019-05-02 2022-06-30 L-Base Co., Ltd. Novel oligopeptide, and pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient
WO2023163094A1 (ja) * 2022-02-25 2023-08-31 日本電気株式会社 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
WO2003011895A2 (en) 2001-07-31 2003-02-13 Soederstroem Karl Petter Compositions and methods for modulation of immune responses
WO2004018667A1 (ja) 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
CA2511538C (en) 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
AU2006248725A1 (en) 2005-05-19 2006-11-23 Glaxosmithkline Biologicals S.A. Vaccine composition comprising B-subunit of E. coli heat toxin and an atigen and an adjuvant
CN103242428B (zh) * 2005-08-09 2015-04-15 肿瘤疗法.科学股份有限公司 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3 (gpc3)的癌症排斥抗原肽以及含有该肽的药物
CN101448938A (zh) 2006-03-28 2009-06-03 佐藤升志 新肿瘤抗原肽
RU2333767C2 (ru) 2006-03-31 2008-09-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
EP2695895A1 (en) 2006-10-17 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
US20100137221A1 (en) 2007-02-27 2010-06-03 University Utah Research Foundation Peptides that interact with topoisomerase i and methods thereof
JP2010538655A (ja) 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
JP5796014B2 (ja) 2009-10-06 2015-10-21 パナセラ ラブス， インコーポレイテッド がんを処置するためのトール様受容体およびトール様受容体アゴニストの使用
IN2014MN01513A (pt) 2012-02-07 2015-09-11 Jolla Inst Allergy Immunolog
US20130217122A1 (en) * 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013143026A1 (en) 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
SG10201707135RA (en) 2013-03-01 2017-10-30 Astex Pharmaceuticals Inc Drug combinations
WO2015168379A2 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
EP3925968A3 (en) 2014-10-07 2022-03-02 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
AU2016230125B2 (en) 2015-03-09 2020-07-16 Nec Corporation Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
EP3797794A1 (en) 2015-04-07 2021-03-31 Cytlimic Inc. Medicine comprising a toll like receptor 3 agonist and a lag-3 protein
AU2017342189B2 (en) * 2016-10-11 2023-09-21 Nec Corporation Medicine

Also Published As

Publication number Publication date
TW201639869A (zh) 2016-11-16
ES2805829T3 (es) 2021-02-15
RU2017135038A3 (pt) 2019-08-30
EP3269733B1 (en) 2020-06-17
TW202115102A (zh) 2021-04-16
AU2016230125A1 (en) 2017-09-21
EP3269733A4 (en) 2018-08-01
US10590179B2 (en) 2020-03-17
US10526388B2 (en) 2020-01-07
AU2016230125B2 (en) 2020-07-16
US10875900B2 (en) 2020-12-29
RU2714117C2 (ru) 2020-02-11
TWI714558B (zh) 2021-01-01
JPWO2016143816A1 (ja) 2018-03-01
JP6898225B2 (ja) 2021-07-07
CA2979168A1 (en) 2016-09-15
US20200157163A1 (en) 2020-05-21
US20190062389A1 (en) 2019-02-28
WO2016143816A1 (ja) 2016-09-15
CN107428815B (zh) 2021-07-09
DK3269733T3 (da) 2020-07-27
US20180105567A1 (en) 2018-04-19
CN107428815A (zh) 2017-12-01
RU2017135038A (ru) 2019-04-08
EP3269733A1 (en) 2018-01-17
CN113388021A (zh) 2021-09-14

Similar Documents

Publication Publication Date Title
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
MX2019010461A (es) Plataforma de identificacion de peptidos inmunogenicos personalizada.
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
ZA201506093B (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
CY1119916T1 (el) Ανοσογονικη συνθεση
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
MX2016002937A (es) Vacuna oncologica.
PE20191248A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MX2017015927A (es) Fragmentos mutantes de proteina ras.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
WO2015107363A3 (en) Mycobacterial antigen composition
MY193807A (en) T-cell receptor and uses thereof
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
NZ729514A (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
MX2018004308A (es) Peptido derivado de foxm1 y vacuna que lo incluye.
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.